The group's principal activities are to acquire, develop and commercialize the acute care hospital products. The group's products are angiomax, also is in the process of developing late stage pharmaceutical products are cleveloxtm and cangrelor. Angiomax is used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing coronary angioplasty. Cleveloxtm is used for short -term control of blood pressure in patients undergoing for cardiac surgery. Cangelor is used for an anticoagulant that prevents platelet clotting in patients undergoing for coronary angioplasty and cardiac surgery. The group operates in the United States.
